公开(公告)号：US20080026485A1

公开(公告)日：2008-01-31

申请号：US11788232

申请日：2007-04-18

申请人： Wolfgang Hueber ,  William Robinson ,  Lawrence Steinman ,  Paul Utz ,  Mark Genovese

发明人： Wolfgang Hueber ,  William Robinson ,  Lawrence Steinman ,  Paul Utz ,  Mark Genovese

IPC分类号： G01N33/564

CPC分类号： G01N33/6869 ,  G01N33/564 ,  G01N33/6854 ,  G01N33/6863 ,  G01N2333/522 ,  G01N2333/523 ,  G01N2333/525 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/545 ,  G01N2800/102 ,  G01N2800/52

摘要： Compositions and methods are provided for prognostic classification of autoimmune disease patients into subtypes, which subtypes are informative of the patient's need for therapy and responsiveness to a therapy of interest. The patterns of circulating blood levels of serum autoantibodies and/or cytokines provides for a signature pattern that can identify patients likely to benefit from therapeutic intervention as well as discriminate patients that have a high probability of responsiveness to a therapy from those that have a low probability of responsiveness. Additionally, serum autoantibody and/or cytokine signature patterns can be utilized to monitor responses to therapy. Assessment of this signature pattern of autoantibodies and/or cytokines in a patient thus allows improved methods of care. In one embodiment of the invention, the autoimmune disease is rheumatoid arthritis.

摘要翻译： 提供组合物和方法用于将自身免疫性疾病患者预后分类为亚型，其中亚型对患者对治疗的需要和对感兴趣的治疗的反应性提供信息。 血清自身抗体和/或细胞因子的循环血液水平的模式提供了可以识别可能受益于治疗性干预的患者的签名模式，以及将具有低概率的那些对治疗具有高反应性概率的患者区分开来 的反应。 另外，可以利用血清自身抗体和/或细胞因子特征图来监测对治疗的反应。 因此，患者自身抗体和/或细胞因子的这种特征图案的评估因此允许改进的护理方法。 在本发明的一个实施方案中，自身免疫性疾病是类风湿性关节炎。

公开(公告)号：US20150125462A1

公开(公告)日：2015-05-07

申请号：US14394617

申请日：2013-04-18

申请人： Stephan Bek ,  Arndt Brachat ,  Wolfgang Hueber ,  Yali Li ,  Ying Wang ,  Roman Yelensky

发明人： Stephan Bek ,  Arndt Brachat ,  Wolfgang Hueber ,  Yali Li ,  Ying Wang ,  Roman Yelensky

IPC分类号： C07K16/24 ,  C12Q1/68

CPC分类号： C07K16/244 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/156

摘要： The disclosure is directed to novel personalized therapies and methods for treating ankylosing spondylitis (AS). Specifically, this disclosure relates to methods of treating a patient having AS by selectively administering an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab, to the AS patient on the basis of that patient being predisposed to have a favorable response to treatment with the IL-17 antagonist. Also disclosed herein are diagnostic methods and transmittable forms of information useful in predicting the likelihood that a patient having AS will respond to treatment with an IL-17 antagonist, e.g., an IL-17 antibody, such as secukinumab.

摘要翻译： 本公开涉及用于治疗强直性脊柱炎（AS）的新型个性化疗法和方法。 具体而言，本公开涉及通过根据该患者倾向于具有有利的方式向AS患者选择性施用IL-17拮抗剂（例如IL-17抗体，例如塞沙单抗）来治疗具有AS的患者的方法。 对IL-17拮抗剂治疗的反应。 本文还公开了诊断方法和可用于预测AS患者对IL-17拮抗剂（例如IL-17抗体例如塞苏单抗）的治疗反应的可能性的可用信息。